Stem cells are a class of undifferentiated biological cells of a multicellular organism that have the potential to produce indefinite numbers of cells of the same type, from which certain types of cells (replication) can be produced by differentiation in the body through early life and growth. There are three types of stem cells: umbilical cord stem cells, adult stem cells, and embryonic stem cells. The umbilical cord stem cells, or multipotent stem cells, are able to produce a small number of different cell types. Adult stem cells originate from adult tissue and redevelop into all the cell types of the organ from the point of origin. Embryonic stem cells, or pluripotent stem cells, are produced from the inner cell mass of a blastocyst (embryo). The stem cell banking procedure includes the collection and preservation of several types of stem cells. Once the collection is complete, these stem cells undergo processing and analysis procedures; viability and different genetic tests are performed on them, and they are cryopreserved and stored for future use. Stem cells are preserved under cryogenic conditions (freezing at a temperature below 150 °C) for longer durations or years in order to retrieve and use them when required for therapeutic purposes, such as to treat diseases that harm the blood and immune system and some metabolic disorders.
A surge in the number of newborns and the rising prevalence of life-threatening genetic disorders and chronic diseases across the world are expected to support market growth over the forecast period. Moreover, growing awareness among people about stem cell therapeutics, coupled with increasing disposable income and healthcare spending, is expected to assist in the market’s growth. On the contrary, high processing and storage costs are anticipated to hinder the market growth during the forecast period.
The umbilical cord stem cells segment is expected to spearhead the market from 2018 to 2026, owing to the higher adoption of umbilical cord stem cells to treat around 80 diseases. The private banks’ segment is anticipated to hold a comparatively higher market share, attributed to high revenue generation from a greater service offering. The presence of major market players in the U.S., coupled with growing awareness among citizens about stem cell banking, is poised to support the dominance of North America during the forecast period.
The global stem cell banking market is segmented on the following basis:
Global Stem Cell Banking Market, by Cell Type, 2016–2026 (US$ Mn)
- Umbilical cord stem cells
- Cord blood
- Cord tissue
- Adult stem cells
- Embryonic stem cells
Global Stem Cell Banking Market, by Bank Type, 2016–2026 (US$ Mn)
- Private Banks
- Public Banks
- Hybrid Banks
Global Stem Cell Banking Market by Application (US$ Mn), 2016-2026
- Cerebral Palsy
Global Stem Cell Banking Market by Geography (US$ Mn), 2016-2026
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified in the global stem cell banking market include:
- CBR Systems, Inc.
- Cryo-Cell International, Inc.
- Cryo-Save AG
- Global Cord Blood Corporation
- Americord Registry LLC
- Smart Cells International Ltd.
- Celgene Corporation
- BrainStorm Cell Therapeutics
- Regenerative Medical Services Pvt. Ltd.
This report offers the following:
- comprehensive overview of the global stem cell banking market, including the current market dynamics
- Elucidation of each market segment based on product approvals, launches, and current and anticipated market dynamics
- Company profiles and the competitive landscape of market leaders operating in the stem cell banking market, comprising key products, operating business areas, and financial analysis